132 related articles for article (PubMed ID: 25152373)
1. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.
Liu H; Gu Y; Yin J; Zheng G; Wang C; Zhang Z; Deng M; Liu J; Jia X; He Z
Cell Signal; 2014 Dec; 26(12):2710-20. PubMed ID: 25152373
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
Wang H; Zhang G; Zhang H; Zhang F; Zhou B; Ning F; Wang HS; Cai SH; Du J
Eur J Pharmacol; 2014 Jan; 723():156-66. PubMed ID: 24333218
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
4. A Bibenzyl from Dendrobium ellipsophyllum inhibits epithelial-to-mesenchymal transition and sensitizes lung cancer cells to anoikis.
Chaotham C; Pongrakhananon V; Sritularak B; Chanvorachote P
Anticancer Res; 2014 Apr; 34(4):1931-8. PubMed ID: 24692728
[TBL] [Abstract][Full Text] [Related]
5. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
6. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
7. Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1).
Xi R; Pun IH; Menezes SV; Fouani L; Kalinowski DS; Huang ML; Zhang X; Richardson DR; Kovacevic Z
Mol Pharmacol; 2017 May; 91(5):499-517. PubMed ID: 28275050
[TBL] [Abstract][Full Text] [Related]
8. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
[TBL] [Abstract][Full Text] [Related]
10. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.
Ambrosio S; Amente S; Saccà CD; Capasso M; Calogero RA; Lania L; Majello B
Oncotarget; 2017 Jan; 8(3):3854-3869. PubMed ID: 27894074
[TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
12. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4.
Jin R; Liu W; Menezes S; Yue F; Zheng M; Kovacevic Z; Richardson DR
J Cell Sci; 2014 Jul; 127(Pt 14):3116-30. PubMed ID: 24829151
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of NDRG1 promote epithelial-mesenchymal transition of colorectal cancer via NF-κB signaling.
Ma J; Gao Q; Zeng S; Shen H
J Surg Oncol; 2016 Sep; 114(4):520-7. PubMed ID: 27338835
[TBL] [Abstract][Full Text] [Related]
15. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
16. The metastatic suppressor NDRG1 inhibits EMT, migration and invasion through interaction and promotion of caveolin-1 ubiquitylation in human colorectal cancer cells.
Mi L; Zhu F; Yang X; Lu J; Zheng Y; Zhao Q; Wen X; Lu A; Wang M; Zheng M; Ji J; Sun J
Oncogene; 2017 Jul; 36(30):4323-4335. PubMed ID: 28346422
[TBL] [Abstract][Full Text] [Related]
17. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.
Piskareva O; Harvey H; Nolan J; Conlon R; Alcock L; Buckley P; Dowling P; Henry M; O'Sullivan F; Bray I; Stallings RL
Cancer Lett; 2015 Aug; 364(2):142-55. PubMed ID: 25960282
[TBL] [Abstract][Full Text] [Related]
18. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.
Sun J; Zhang D; Bae DH; Sahni S; Jansson P; Zheng Y; Zhao Q; Yue F; Zheng M; Kovacevic Z; Richardson DR
Carcinogenesis; 2013 Sep; 34(9):1943-54. PubMed ID: 23671130
[TBL] [Abstract][Full Text] [Related]
19. SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer.
Liu L; Zhang J; Yang X; Fang C; Xu H; Xi X
PLoS One; 2015; 10(9):e0138515. PubMed ID: 26407074
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
Yan YR; Xie Q; Li F; Zhang Y; Ma JW; Xie SM; Li HY; Zhong XY
Neuropathology; 2014 Apr; 34(2):128-34. PubMed ID: 24112388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
